DNER and cancer: BET inhibitor (BETi) epi-drugs have demonstrated anti-cancer activity in both pre-clinical and clinical trials and function by binding reversibly to the bromodomain of BET proteins and subsequently disrupt vital histone-protein interactions [19, 20].